Verdence Capital Advisors LLC Purchases 259 Shares of Maximus, Inc. $MMS

Verdence Capital Advisors LLC grew its position in shares of Maximus, Inc. (NYSE:MMSFree Report) by 3.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 7,728 shares of the health services provider’s stock after acquiring an additional 259 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Maximus were worth $542,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC boosted its position in shares of Maximus by 218.6% during the 2nd quarter. CWM LLC now owns 7,244 shares of the health services provider’s stock valued at $509,000 after acquiring an additional 4,970 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Maximus by 32.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 8,607 shares of the health services provider’s stock valued at $604,000 after acquiring an additional 2,092 shares during the last quarter. Inspire Investing LLC increased its position in Maximus by 251.8% during the second quarter. Inspire Investing LLC now owns 17,751 shares of the health services provider’s stock valued at $1,246,000 after acquiring an additional 12,705 shares during the last quarter. Blue Trust Inc. increased its position in Maximus by 31.0% during the second quarter. Blue Trust Inc. now owns 1,609 shares of the health services provider’s stock valued at $113,000 after acquiring an additional 381 shares during the last quarter. Finally, Total Wealth Planning & Management Inc. increased its position in Maximus by 13.1% during the second quarter. Total Wealth Planning & Management Inc. now owns 5,875 shares of the health services provider’s stock valued at $412,000 after acquiring an additional 679 shares during the last quarter. 97.21% of the stock is currently owned by institutional investors.

Maximus Price Performance

MMS opened at $84.76 on Wednesday. The business’s 50-day moving average is $87.09 and its two-hundred day moving average is $76.39. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $93.73. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.27 and a quick ratio of 2.27. The firm has a market capitalization of $4.78 billion, a PE ratio of 15.61 and a beta of 0.57.

Maximus (NYSE:MMSGet Free Report) last posted its earnings results on Thursday, August 7th. The health services provider reported $2.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.77. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. Research analysts anticipate that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 1.4%. The ex-dividend date is Friday, November 14th. Maximus’s payout ratio is 22.10%.

Analysts Set New Price Targets

A number of research analysts have weighed in on MMS shares. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 26th. Weiss Ratings upgraded shares of Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $90.00.

Check Out Our Latest Report on Maximus

Insider Transactions at Maximus

In other Maximus news, insider Michelle F. Link sold 1,610 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total value of $146,284.60. Following the completion of the sale, the insider owned 13,508 shares of the company’s stock, valued at approximately $1,227,336.88. This trade represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Maximus Profile

(Free Report)

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.

Further Reading

Institutional Ownership by Quarter for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.